Mirador Therapeutics announced it is advancing multiple clinical-stage programs across Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis, with more than 10 clinical readouts expected by the end of 2027.
The San Diego-based company, which is developing precision medicines for immune-mediated inflammatory and fibrotic diseases, said its strategy emphasizes novel targets, precision medicine, rational combinations and multi-specific approaches aimed at improving outcomes for patients who remain untreated or inadequately served by existing therapies.
Mirador said its progress is supported by its Mirador360 (M360) precision discovery and development engine, which it says leverages more than 2.5 million patient profiles across immunology and inflammation. The company said M360 integrates these data with machine learning to support target discovery and validation, patient stratification, and prioritization of combinations and indication expansion.
Separately, Mirador disclosed that it closed a $250 million Series B financing in the third quarter of 2025, bringing total capital raised to more than $650 million since the company launched in March 2024. Mirador said the proceeds are intended to support proof-of-concept across its current programs and advance additional pipeline candidates.
New investors in the Series B included T. Rowe Price Investment Management, Adage Capital Partners, and additional funds managed by Fidelity Management & Research Company. Existing investors participating included ARCH Venture Partners, OrbiMed, Fairmount, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Woodline Partners, and Venrock Healthcare Capital Partners, among others.
KEY QUOTE:
“Driving meaningful progress in immuno-fibrotic disease treatment requires moving beyond incremental innovation and monotherapy toward novel targets, precision medicine, rational combinations, and multi-specifics… In less than two years, our team has advanced multiple clinical-stage assets with first- and/or best-in-class potential across four major indications… with 10 or more clinical readouts expected by year-end 2027.” “We have been intentional about building Mirador with the capabilities and resources to deliver long-term impact… In 2026, we will remain laser-focused on capital efficiency and disciplined execution to sustain momentum.”
Mark C. McKenna, Chairman and CEO, Mirador Therapeutics
